✦ LIBER ✦

Bisphosphonates in the Treatment of Metastatic Breast Cancer

✍ Scribed by Jean-Jacques Body

Book ID: 110331011
Publisher: Springer US
Year: 2001
Tongue: English
Weight: 71 KB
Volume: 6
Category: Article
ISSN: 1083-3021
DOI: 10.1023/a:1014795216669

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of YM-175, a new bisphosphonate

Efficacy of YM-175, a new bisphosphonate, in the treatment of metastatic bone tumor from breast cancer and its effect on scintigraphy

✍ Mitsuru Koizumi; Hiroshi Sekine; Manabu Aoki; Shinya Hayashi; Takashi Yamashita; 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 856 KB

Bisphosphonates in Metastatic Breast Can

Bisphosphonates in Metastatic Breast Cancer

✍ Peter Schmid; Kurt Possinger 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 81 KB

Bisphosphonate treatment and radiotherap

Bisphosphonate treatment and radiotherapy in metastatic breast cancer

✍ A. Ugur Ural; Ferit Avcu; Yusuf Baran 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 180 KB

Herceptin in the treatment of metastatic

Herceptin in the treatment of metastatic breast cancer

✍ G. Konecny; M. Untch; M. Pegram 📂 Article 📅 1999 🏛 Springer 🌐 German ⚖ 120 KB

Optimizing the treatment of metastatic b

Optimizing the treatment of metastatic breast cancer

✍ Julie R. Gralow 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 193 KB

Oral medroxyprogesterone in the treatmen

Oral medroxyprogesterone in the treatment of metastatic breast cancer

✍ Takuma Nemoto; Jashbha1 Patel; Dutzu Rosner; Thomas L. Dao 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB

In 47 postmenopausal women with evaluable breast cancer, oral medroxyprogesterone acetate (MPA) was given at a daily dose level of 400 mg. Patients with negative estrogen receptors, poor performance status , or nonresponse to previous endocrine therapy were excluded from this study. There were 25 (